In Vivo Tau Imaging in Alzheimer's Disease and Other Dementias

Mesial temporal tau in amyloid-β-negative cognitively normal older persons

N Krishnadas, V Doré, C Groot, F Lamb, P Bourgeat, SC Burnham, K Huang, AMY Goh, CL Masters, VL Villemagne, CC Rowe

2022-12-01

Background: Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET trac..

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology

V Doré, S Bullich, CC Rowe, P Bourgeat, S Konate, O Sabri, AW Stephens, H Barthel, J Fripp, CL Masters, L Dinkelborg, O Salvado, VL Villemagne, S De Santi

2019-06-01

Introduction: ¹⁸F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also use..

Imaging tau and amyloid-? proteinopathies in Alzheimer disease and other conditions

VL Villemagne, V Doré, SC Burnham, CL Masters, CC Rowe

2018-04-01

Most neurodegenerative disorders are associated with aggregated protein deposits. In the case of Alzheimer disease (AD), extracell..

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids

CC Rowe, V Doré, G Jones, D Baxendale, RS Mulligan, S Bullich, AW Stephens, S De Santi, CL Masters, L Dinkelborg, VL Villemagne

2017-11-01

Purpose: The Centiloid (CL) method enables quantitative values from Aβ-amyloid (Aβ) imaging to be expressed in a universal unit pr..

Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle

CJ Perry, AJ Lawrence

2017-01-01

Any type of behavioral change is an effortful process. Thus, the process of behavioral therapy, where clients seek to change malad..

Aβ-amyloid and Tau Imaging in Dementia

VL Villemagne, V Doré, P Bourgeat, SC Burnham, S Laws, O Salvado, CL Masters, CC Rowe

2017-01-01

The introduction of in vivo imaging of Aβ-amyloid (Αβ) pathology more than a decade ago, transformed the assessment of Alzheimer d..

Standardized Expression of 18F-NAV4694 and 11C-PiB b-amyloid PET results with the centiloid scale

CC Rowe, G Jones, V Dore, S Pejoska, L Margison, RS Mulligan, J Gordon Chan, K Young, VL Villemagne

2016-08-01

A common quantitative output value for PET measures of β-amyloid (Aâ) binding across tracers and methods would allow better compar..

Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions

VL Villemagne, N Okamura

2016-02-01

In vivo tau imaging allows a deeper understanding of tau deposition in the brain, providing insights into the causes, diagnosis an..

Untangling tau imaging

VL Villemagne, N Okamura, CC Rowe

2016-01-01

In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allow..

Tau imaging: Early progress and future directions

VL Villemagne, MT Fodero-Tavoletti, CL Masters, CC Rowe

2015-01-01

Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation in the brain, facilitating research int..

Voyage au bout de la nuit: Aβ and tau imaging in dementias

MD Zwan, N Okamura, MT Fodero-Tavoletti, S Furumoto, CL Masters, C Rowe, VL Villemagne

2014-12-01

The last decade has witnessed the development and characterization of tracers for the evaluation of neuropathology in vivo.The int..

Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies

MT Fodero-Tavoletti, S Furumoto, L Taylor, CA McLean, RS Mulligan, I Birchall, R Harada, CL Masters, K Yanai, Y Kudo, CC Rowe, N Okamura, VL Villemagne

2014-02-26

Introduction: The introduction of tau imaging agents such as 18F-THK523, offers new hope for the in vivo assessment of tau deposit..

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease

VL Villemagne, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, J Hodges, R Harada, P Yates, O Piguet, S Pejoska, V Doré, K Yanai, CL Masters, Y Kudo, CC Rowe, N Okamura

2014-01-01

Purpose: Diagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A n..

In vivo tau imaging: Obstacles and progress

VL Villemagne, N Okamura

2014-01-01

The military conflicts of the last decade have highlighted the growing problem of traumatic brain injury in combatants returning f..

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET

N Okamura, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, R Harada, P Yates, S Pejoska, Y Kudo, CL Masters, K Yanai, CC Rowe, VL Villemagne

2014-01-01

Non-invasive imaging of tau pathology in the living brain would be useful for accurately diagnosing Alzheimer's disease, tracking ..